Home›Trial›NCT05329766
🔬NCT05329766Phase 2ACTIVE NOT RECRUITING

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Study Summary

The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).

Conditions
Gastrointestinal Tract Malignancies
Interventions / Drugs
DomvanalimabQuemliclustatZimberelimabFluorouracilLeucovorinOxaliplatin
View on ClinicalTrials.gov ↗
Sponsor
ARQT
Arcus Biosciences
Immuno-Oncology
F29/100
Study Details
Enrollment332 participants
Primary Completion—
Lead SponsorArcus Biosciences, Inc.
Data Retrieved2026-04-11 02:54:25.662795+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.